How to access Casgevy from India — the named-patient coordination pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

An Indian patient with severe sickle cell disease (recurrent painful vaso-occlusive crises despite standard therapy) or transfusion-dependent beta-thalassemia may be evaluated by their treating haematologist for Casgevy (exagamglogene autotemcel). Casgevy is FDA-approved, developed by Vertex Pharmaceuticals in collaboration with CRISPR Therapeutics, and is the first CRISPR-edited cell therapy approved for these haemoglobinopathies. Because Casgevy is an autologous cell therapy — manufactured individually from each patient's own stem cells — access involves a qualified-treatment-centre (QTC) model that differs materially from traditional drug import, typically requiring international referral to a Casgevy-authorised centre.

This guide explains the legal and operational pathway, what your haematologist needs to coordinate, typical timing and cost bands, and where Reserve Meds fits in.

The clinical situation

Casgevy is a one-time infusion of genetically edited autologous haematopoietic stem cells, where CRISPR-Cas9 is used to disrupt a regulatory region of BCL11A and reactivate foetal haemoglobin production. Treatment involves: mobilisation and apheresis to collect stem cells, shipment of cells to the manufacturer, a manufacturing window of several weeks, high-dose myeloablative conditioning chemotherapy, infusion of the edited cells, and an extended inpatient recovery period for engraftment. Eligibility is based on severe SCD with recurrent crises (or transfusion-dependent beta-thalassemia) and fitness for myeloablative conditioning. Your haematologist confirms eligibility and identifies an authorised QTC.

Is Casgevy legally accessible for Indian patients?

Casgevy cannot be "imported" as a drug — it is manufactured from your own stem cells and must be administered at a Casgevy-qualified cell-therapy treatment centre. Access for Indian patients therefore typically follows one of two patterns, both operating within the Central Drugs Standard Control Organisation (CDSCO) medical-referral and personal-import frameworks:

Pattern A — Cross-border referral to an authorised QTC. The patient travels to a Casgevy-qualified centre (in the US, Europe, or select international centres partnering with the manufacturer) for the full workup, mobilisation, apheresis, conditioning, infusion, and recovery.

Pattern B — Hybrid coordination with an Indian tertiary centre partnering with the manufacturer's qualified network. Where an Indian centre has the cell-therapy infrastructure and a formal partnership, portions of workup and follow-up may be localised in coordination with the QTC.

CDSCO's medical-referral and personal-import frameworks support both patterns, with documentation covering medical necessity, treatment-centre identification, and the return-to-India care plan.

How the pathway works, step by step

1. Consultation with your haematologist. Eligibility assessment including crisis/transfusion history, organ-system baseline, and fitness for myeloablative conditioning.
2. Treatment-centre identification. Reserve Meds coordinates referral to a Casgevy-qualified centre through our international care-coordination network.
3. CDSCO referral documentation. Your physician files the cross-border medical-referral dossier.
4. Mobilisation and apheresis. Conducted at the QTC per manufacturer protocol; manufacturing begins after cell collection.
5. Manufacturing window (several weeks). Bridging transfusion support and supportive care may be given locally in India or at the QTC.
6. Conditioning, infusion, and inpatient engraftment monitoring. Administered at the QTC with extended inpatient stay; handover to your Indian haematologist for long-term follow-up.

What documentation your physician needs

Your physician will typically need to provide:

• A clinical rationale letter confirming diagnosis, crisis/transfusion history, organ-system status, and Casgevy as the indicated treatment
• Verification of their Indian medical registration (NMC / state council)
• Identification of the authorised Casgevy QTC and the cross-border referral plan
• Patient identifier (anonymised reference where possible)
• A long-term follow-up plan for return to India

Reserve Meds provides a coordination kit that bundles the templates CDSCO reviewers and QTCs expect to see for cross-border gene-therapy referrals.

Costs and timing

Casgevy's US list price sits in an indicative 2026 range of roughly USD 2.0–2.3 million for the gene-therapy product itself. Total cost of care — including inpatient stay, conditioning, mobilisation, apheresis, engraftment monitoring, and bridging care — typically runs substantially higher when delivered at a US QTC. International travel, extended accommodation for caregivers, and coordination add incremental cost. Cost framing is one-time for the therapy itself, but families should plan for several years of lifetime monitoring. Reserve Meds issues a full transparent quote at the start of intake.

Indicative timing — not guaranteed — from intake to infusion typically runs 12–24 weeks, driven primarily by the manufacturing window and QTC calendar. Inpatient stay around conditioning and engraftment is typically four to six weeks or longer.

Reserve Meds is in pre-launch. Fulfilment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.

A culturally-aware note: India carries one of the world's largest thalassemia and SCD burdens, with regional clustering in tribal populations, Gujarat, Maharashtra, and parts of central and southern India. Cell-therapy journeys require a family caregiver present throughout the extended inpatient stay abroad; our coordination includes caregiver travel, visa support, accommodation near the QTC, and vegetarian or regional dietary preferences at the partnering centres.

Reserve Meds's role

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine and cell therapy. For Casgevy specifically, we provide:

• QTC referral. Coordination with authorised Casgevy centres through our clinical network.
• Documentation. Cross-border referral and CDSCO named-patient package.
• Logistics. Patient and caregiver travel, accommodation, and post-infusion return-home planning.
• Concierge case lead. A named point of contact for the family throughout the extended treatment journey.

What we do not do: we are not the prescriber, we do not practise medicine, we do not manufacture the cell product, and we are not the treatment centre. All clinical decisions remain with your treating haematologist and the QTC. We operate on a waitlist basis during our pre-launch phase.

Frequently asked

Is this legal in India? Yes, when executed through the CDSCO medical-referral and personal-import framework with a qualified international treatment centre. See our trust and compliance page.

How long will we be abroad? Most Casgevy journeys require 3–6 months away from home, covering workup, mobilisation, manufacturing, conditioning, infusion, and engraftment monitoring. Your QTC will confirm.

Is Casgevy a cure? Pivotal study data demonstrate durable freedom from vaso-occlusive crises (in SCD) and transfusion independence (in beta-thalassemia) in treated patients. Your haematologist will discuss realistic outcome expectations and the long-term surveillance plan.

What about the conditioning chemotherapy risks? Myeloablative conditioning carries substantial short- and long-term risks including infertility. Fertility preservation counselling is a standard pre-treatment step. Your haematology team will explain the full profile.

Can this be done entirely in India? In early years post-approval, full end-to-end Casgevy delivery is concentrated at manufacturer-authorised QTCs internationally. Hybrid Indian-partner arrangements evolve over time; your haematologist has current information.

Next step — join the first-cohort waitlist

Reserve Meds is opening to a limited first cohort in 2026 for cell-therapy coordination. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Casgevy coordination.

Add me to the Casgevy waitlist

---

Composite case examples. Reserve Meds is in pre-launch. This content is for general information and does not constitute medical advice.

Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.